Oncothyreon (ONTY) Reports Q4 Loss of Per Share $0.10, Offers Guidance

Oncothyreon (NASDAQ: ONTY) reported Q4 EPS of ($0.10), versus ($0.30) reported last year.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. Oncothyreon is providing this guidance as a convenience to investors and assumes no obligation to update it.

Oncothyreon currently expects operating expenses in 2016 to be higher than in 2015. This increase will primarily be related to expenditures associated with the Phase 2 trial of ONT-380. Oncothyreon currently expects cash used in operations in 2016 to be approximately $38.0 million to $40.0 million. With cash, cash equivalents and investments of $56.4 million as of December 31, 2015, Oncothyreon estimates that its cash, cash-equivalents and investments will be sufficient to fund operations for at least the next 12 months.

For earnings history and earnings-related data on Oncothyreon (ONTY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c